In our study, we observed that circulating endocan levels in patients with microvascular angina (MVA) were higher than for the controls and comparable to patients with obstructive coronary artery disease (CAD).
Endocan is expressed by the vascular endothelium and circulates in the bloodstream. 3 An increase in serum level of endocan reflects endothelial activation. 4, 5 Endocan may influence both the recruitment of circulating lymphocytes to inflammatory sites and leukocyte function-associated antigen 1-dependent leukocyte adhesion and activation. 6 This pathway may play an important role in early atherogenesis. 7 Thus, the evidence suggests that endocan may play a role in the initiation of atherosclerosis. In addition, endothelial dysfunction is involved in both CAD and MVA. 8 In our study, increased endocan levels in both diseases indicate a common inflammatory pathway where endocan might be involved.
Because endothelial activation reflects a proinflammatory state, we suggest that we define endocan in the forefront of the fight against endothelial inflammation rather than as an end point marker.
